首页> 外文期刊>Journal of cardiology >Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)
【24h】

Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)

机译:因心力衰竭加重而住院期间患者的特征,治疗和结果-日本心脏病心力衰竭心脏登记系统(JCARE-CARD)的一份报告

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The characteristics, in-hospital management, and outcomes of patients hospitalized with worsening heart failure (HF) have been described by large-scale registries performed mainly in the USA and Europe. However, little information is available in Japan. We thus clarified the characteristics and clinical status as well as in-hospital management and outcomes among patients hospitalized with worsening HF in Japan and compared them with those reported in previous studies. Methods: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics and treatments in patients hospitalized with worsening HF. From the total cohort of JCARE-CARD, 1677 patients were randomly selected and their detailed data during acute phase were collected as another registry database in the present study. The characteristics, in-hospital management, and outcomes were analyzed. Results: The mean age was 70.7 years and 59.4% were male. Etiology was ischemic in 34.0% and mean left ventricular ejection fraction was 42.5%. Carperitide was highly used as in-hospital management in Japan (33.5%) compared to the use of nesiritide in the USA (8-11%). The use of angiotensin-converting enzyme inhibitors was lower and angiotensin II receptor blockers (ARB) were more commonly used in this study compared to other studies in the USA and Europe. In-hospital crude mortality rate was comparable among studies (4-8%), however, length of stay was longer in Japan (15-20 versus 4-9 days). Conclusions: The characteristics, clinical status, and laboratory data on admission in patients hospitalized with worsening HF were similar between the present study and previous Japanese and western studies. Management was also similar except for higher use of carperitide and ARB. The most striking difference between Japanese registries and those from the USA and Europe was the longer length of stay.
机译:背景:主要在美国和欧洲进行的大规模注册已描述了因心力衰竭(HF)恶化而住院的患者的特征,住院管理和结局。但是,日本几乎没有信息。因此,我们澄清了在日本因心力衰竭而住院的患者的特征和临床状况以及院内管理和结局,并将其与以前的研究进行了比较。方法:日本心脏病心力衰竭心脏注册中心(JCARE-CARD)前瞻性研究了因心衰而住院的患者的特征和治疗方法。从JCARE-CARD的全部队列中,随机选择1677例患者,并将其急性期的详细数据作为本研究中的另一个注册表数据库进行收集。分析其特征,住院管理和结果。结果:平均年龄为70.7岁,男性为59.4%。病因是缺血性,占34.0%,平均左心室射血分数是42.5%。与美国使用奈西立肽(8-11%)相比,日本将卡哌利肽(33.5%)高度用作医院内治疗。与美国和欧洲的其他研究相比,本研究中血管紧张素转换酶抑制剂的使用率较低,并且血管紧张素II受体阻滞剂(ARB)的使用更为广泛。在研究中,住院期间的粗死亡率相当(4-8%),但是在日本的住院时间更长(15-20天比4-9天)。结论:本研究与先前的日本和西方研究之间,心衰恶化的住院患者的特征,临床状况和入院实验室数据相似。除较高使用卡培肽和ARB外,管理方法也相似。日本注册管理机构与美国和欧洲注册管理机构之间最显着的区别是停留时间更长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号